Skip to content
Hair Pipeline
enfr
← Recruiting trials
NCT07617597Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

In the register

The register attaches this trial to Deuruxolitinib (Leqselvi) (Sun Pharmaceutical), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status
Recruiting
Declared phase
Phase 3
Sponsor
Sun Pharma Japan Limited
Participants (registry)
78
Start
June 2026
Primary completion
February 2028 (planned)
Study completion
September 2028 (planned)
Last registry update
September 2026
Countries
Japan

Conditions studied: Alopecia Areata

Interventions: Deuruxolitinib, Placebo, Deuruxolitinib

Full record on ClinicalTrials.gov ↗

Other trials of Deuruxolitinib (Leqselvi)

  • NCT07133308Phase 3Recruiting

    Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

  • NCT05041803Phase 3Completed

    European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  • NCT04797650Phase 3Completed

    Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

  • NCT04784533Phase 2Completed

    A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

  • NCT04518995Phase 3Completed

    Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

  • NCT03941548Phase 2Completed

    Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

  • NCT03898479Phase 2/3Active, not recruiting

    Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  • NCT03811912Phase 2Completed

    Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

  • NCT03137381Phase 2Completed

    Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.